Status:

UNKNOWN

Rapid and Accurate Detection of Major Mycobacterium Species in Pulmonary Infection Based on GenSeizer Platform

Lead Sponsor:

Shanghai Pulmonary Hospital, Shanghai, China

Conditions:

Mycobacterium Pulmonary Infection

Eligibility:

All Genders

16-70 years

Brief Summary

Comparison of rapid detection methods of mycobacterial pathogens, GenSeizer v.s. PCR reverse hybridization.

Detailed Description

The investigators developed a new platform called GenSeizer, which combines bioinformatics analysis of a large dataset with multiplex PCR-based targeted gene sequencing, to identify eleven major Mycob...

Eligibility Criteria

Inclusion

  • Suspected cases of mycobacterial lung infection

Exclusion

  • No sputum
  • Refused or unable to tolerate bronchoscopy

Key Trial Info

Start Date :

June 28 2021

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

August 30 2024

Estimated Enrollment :

400 Patients enrolled

Trial Details

Trial ID

NCT04345939

Start Date

June 28 2021

End Date

August 30 2024

Last Update

October 6 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Haiqing Chu

Shanghai, China

Rapid and Accurate Detection of Major Mycobacterium Species in Pulmonary Infection Based on GenSeizer Platform | DecenTrialz